SciSparc Expands Patent Portfolio with Psychedelic-PEA Combinations…

Event summary

SciSparc's subsidiary NeuroThera filed three U.S. patent applications covering LSD, ketamine, and ibogaine combined with PEA technology for mental health and substance use disorders.
The patents build on prior filings for MDMA-PEA combinations, expanding NeuroThera's intellectual property portfolio.
Collaboration with Clearmind continues to focus on combining PEA with psychedelic compounds for novel therapeutics.

The big picture

The expansion of NeuroThera's patent portfolio reflects the growing interest in psychedelic-assisted therapies for mental health disorders. As regulatory pathways for psychedelics evolve, SciSparc's focus on combining these compounds with PEA technology positions it in a niche segment of the biopharmaceutical industry. The collaboration with Clearmind underscores a strategic shift toward proprietary combinations that could differentiate NeuroThera's offerings in a crowded market.

What we're watching

Patent Strategy: How NeuroThera will leverage this expanded IP portfolio to attract partnerships or licensing deals.
Clinical Validation: Whether the PEA-psychedelic combinations will demonstrate sufficient efficacy in clinical trials to justify patent protection.
Market Positioning: The pace at which NeuroThera can commercialize these patents in a competitive psychedelics market.